Our Commitment
As a portfolio company of Paragon Biosciences, Emalex is unceasing in its pursuit to improve the lives of people living with central nervous system movement disorders and fluency disorders through meaningful scientific breakthroughs. We are committed to utilizing internal and external resources to pursue and advance treatment options for patients with high unmet needs. In addition, we collaborate with patient advocacy organizations to raise awareness and support their educational outreach and communication efforts.
Leadership
Our leadership team is comprised of remarkable professionals who are passionate about innovative solutions that improve the lives of people living with chronic central nervous system conditions.
Eric Messner
Chief Business Officer
Atul R. Mahableshwarkar, MD, DFAPA
Chief Medical Officer and
Senior Vice President
of Drug Development
Frederick Munschauer, M.D., MSc., FAAN
Chief Medical Officer, Neurology and
Senior Vice President, Medical and
Scientific Affairs
Jay White, Ph.D.
Vice President, Chemistry, Manufacturing and Controls (CMC)
Jenny Swalec
Vice President, Regulatory Affairs and Quality Assurance
Karl Karduck
Senior Director, Good Manufacturing Practice (GMP) Quality Assurance
David Kim
Senior Director, Clinical Operations
Kerensa Saljooqi
Senior Director, Clinical Operations
Joy Schleyer
Senior Director, Clinical Operations
Christine H. Soulje, Ph.D.
Senior Director, Product Development
Tom Stothoff
Senior Director, Chemistry, Manufacturing and Controls (CMC) Regulatory Affairs
